NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL
Ibrutinib plus Rituximab is now approved by the FDA in Waldenström’s Macroglobulinemia (WM), a rare form of non-Hodgkin’s lymphoma and a sister cancer to CLL. WM is much less common than CLL. With this approval, ibrutinib is now approved for adults with WM in combination with rituximab, representing the first chemotherapy-free combination treatment specifically indicated for this blood cancer.
For more information, click here to see the press release.
While not specifically CLL news, the more options for related blood cancers, the better for all of us as we learn from each other’s experience with the drugs.
Related posts